Related references
Note: Only part of the references are listed.RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes
Andrea M. Pesch et al.
JCI INSIGHT (2022)
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
Luca Gianni et al.
NPJ BREAST CANCER (2022)
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer
Theresa E. Hickey et al.
NATURE MEDICINE (2021)
Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Jessica L. Christenson et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Apalutamide radio-sensitisation of prostate cancer
Christos Kakouratos et al.
BRITISH JOURNAL OF CANCER (2021)
Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment
Tiecheng Wang et al.
CANCER CELL INTERNATIONAL (2021)
ERα is an RNA-binding protein sustaining tumor cell survival and drug resistance
Yichen Xu et al.
CELL (2021)
Modulating the Radiation Response for Improved Outcomes in Breast Cancer
Andrea M. Pesch et al.
JCO PRECISION ONCOLOGY (2021)
TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination
Benjamin C. Chandler et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Androgen receptor degraders over come common resistance mechanisms developed during prostate cancer treatment
Steven Kregel et al.
NEOPLASIA (2020)
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
Anna R. Michmerhuizen et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers
Andrea M. Pesch et al.
CLINICAL CANCER RESEARCH (2020)
ARe we there yet? Understanding androgen receptor signaling in breast cancer
Anna R. Michmerhuizen et al.
NPJ BREAST CANCER (2020)
Non-canonical AR activity facilitates endocrine resistance in breast cancer
KeeMing Chia et al.
ENDOCRINE-RELATED CANCER (2019)
Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?
Celestia Higano
NATURE REVIEWS UROLOGY (2019)
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation
Anna R. Michmerhuizen et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
Xin Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
L. Gerratana et al.
CANCER TREATMENT REVIEWS (2018)
The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome
Carmela Ricciardelli et al.
CLINICAL CANCER RESEARCH (2018)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
Tiffany A. Traina et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Hitisha K. Patel et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
Norihito Shibata et al.
SCIENTIFIC REPORTS (2018)
EXTH-15. TARGETING ANDROGEN SIGNALING IN GLIOBLASTOMA (GBM) USING SEVITERONEL (SEVI), A CYP17 LYASE AND ANDROGEN RECEPTOR (AR) INHIBITOR, ALONE AND IN COMBINATION WITH RADIATION (RT)
Hanshi Sun et al.
NEURO-ONCOLOGY (2018)
Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
Corey Speers et al.
NPJ BREAST CANCER (2017)
Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
Corey Speers et al.
CLINICAL CANCER RESEARCH (2016)
A genetic basis for the variation in the vulnerability of cancer to DNA damage
Brian D. Yard et al.
NATURE COMMUNICATIONS (2016)
HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo
Jing Hou et al.
ONCOTARGET (2016)
Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells
Marina Holler et al.
PLOS ONE (2016)
Targeting Androgen/Estrogen Receptors Crosstalk in Cancer
Michalis V. Karamouzis et al.
TRENDS IN CANCER (2016)
Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation
Daniel E. Spratt et al.
CANCER RESEARCH (2015)
Targeting the androgen receptor in prostate and breast cancer: several new agents in development
Tracy Proverbs-Singh et al.
ENDOCRINE-RELATED CANCER (2015)
TBCRC 024 Initial Results: A Multicenter Phase 1 Study of Veliparib Administered Concurrently With Chest Wall and Nodal Radiation Therapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer
R. Jagsi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Paul J. Toren et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer
Felix Y. Feng et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Revising the role of the androgen receptor in breast cancer
F. M. Fioretti et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Karim Fizazi et al.
LANCET ONCOLOGY (2014)
Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells
Jing Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult
Jonathan F. Goodwin et al.
CANCER DISCOVERY (2013)
Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
William R. Polkinghorn et al.
CANCER DISCOVERY (2013)
Androgen Receptor Influences on Body Defense System via Modulation of Innate and Adaptive Immune Systems Lessons from Conditional AR Knockout Mice
Jiann-Jyh Lai et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
HER2-Associated Radioresistance of Breast Cancer Stem Cells Isolated from HER2-Negative Breast Cancer Cells
Nadire Duru et al.
CLINICAL CANCER RESEARCH (2012)
In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer
Xiaomeng Zhang et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2011)
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
Leo A. Niemeier et al.
MODERN PATHOLOGY (2010)
Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth
David G. DeNardo et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2007)
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines
Eric Badia et al.
CURRENT MEDICINAL CHEMISTRY (2007)
Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells
Rumi S. Bhattacharyya et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Letrozole sensitizes breast cancer cells to ionizing radiation
D Azria et al.
BREAST CANCER RESEARCH (2005)
Expression of ErbB2 enhances radiation-induced NF-κB activation
GZ Guo et al.
ONCOGENE (2004)
Amifostine: Is there evidence of tumor protection?
MI Koukourakis
SEMINARS IN ONCOLOGY (2003)
Share Paper
